Companies › BioAegis Therapeutics
2 active drug programs in 2 registered trials: 2 Phase 2; Infectious disease, Other; next expected readout Oct 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Rhu-pGSN Recombinant human gelsolin - actin-scavenging protein that reduces inflammatory cell damag | GSN | Phase 2 | Acute Respiratory Distress Syndrome | Oct 2027 |
| Recombinant human plasma gelsolin Plasma gelsolin acts as a scavenger of actin released from damaged cells and modulates inf | GSN | Phase 2 | Decompression Sickness | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06216366 | Recombinant human plasma gelsolin | Phase 2 | Decompression Sickness | Other | Sep 2025 |
| NCT05947955 | Rhu-pGSN | Phase 2 | Acute Respiratory Distress Syndrome | Infectious disease | Oct 2027 |
–
Freya Biosciences ApS Aligos Therapeutics BioVersys SAS Meitheal Pharmaceuticals Shanghai Yidian Pharmaceutical Technology Development
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.